CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net income	$ 21,411	$ 16,617	$ 28,353
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	20,868	15,778	10,507
Non-cash interest expense	7,536	4,248	3,977
Stock-based compensation expense	12,847	10,192	6,747
Deferred tax expense	(624)	71	(24,679)
Loss on extinguishment of debt	5,650
Other	663	(3)	64
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(7,726)	(6,101)	(6,888)
Royalties and other receivables	(104)	7	644
Unbilled receivables	2,146	(2,602)	0
Inventories	(9,314)	(4,042)	605
Prepaid expenses and other assets	(661)	(1,769)	(1,304)
Operating lease right of use assets	(4,662)
Accounts payable	662	2,266	807
Accrued expenses	13,096	(1,398)	(1,993)
Operating lease liability	5,447
Long-term liabilities	(19)	(494)	611
Total cash provided by operating activities	67,216	32,770	17,451
Cash flows from investing activities:
Purchases of marketable securities			(47)
Redemption of marketable securities			19,600
Additions to capitalized software costs	(4,650)	(2,147)
Developed technology intangible asset payment		(1,255)
Purchases of property, plant and equipment	(18,504)	(10,635)	(5,454)
Total cash used in investing activities	(205,308)	(14,037)	(98,696)
Cash flows from financing activities:
Proceeds from issuance of convertible debt, net	278,466
Proceeds from issuance of common stock, net	320,713		129,309
Exercise of stock options	1,167	3,418	2,351
Repayment of senior convertible notes	(114,989)	(11)
Payment of tax withholding obligation on vesting of restricted stock	(490)		(1,715)
Total cash provided by financing activities	484,867	3,407	129,945
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(3,190)	(2,077)	2,376
Net increase in cash, cash equivalents and restricted cash	343,585	20,063	51,076
Cash, cash equivalents and restricted cash, beginning of period	193,822	173,759	122,683
Cash, cash equivalents and restricted cash, end of period	537,407	193,822	173,759
Supplemental disclosure of cash flow information:
Income taxes paid	6,505	4,046	4,021
Interest paid	1,484	2,444	2,444
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	8,663
Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes	198,757
Non-cash effect of adoption of ASU 2016-16		5,609
Property, plant and equipment related to lease incentives		$ 2,270
Payment of contingent consideration in common stock			1,063
Spectrum Lifesciences Inc
Cash flows from investing activities:
Acquisition of assets, net of cash acquired			(112,795)
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition			$ 247,575
C Technologies Inc
Cash flows from investing activities:
Acquisition of assets, net of cash acquired	(182,154)
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	$ 53,938